Investment Analysts’ Weekly Ratings Changes for Hinge Health (HNGE)

A number of research firms have changed their ratings and price targets for Hinge Health (NYSE: HNGE):

• 7/21/2026 – Hinge Health had its price target raised by Canaccord Genuity Group Inc. from $76.00 to $100.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Hinge Health had its price target raised by Barclays PLC from $70.00 to $97.00. They now have an “overweight” rating on the stock.
• 7/13/2026 – Hinge Health had its price target raised by KeyCorp from $90.00 to $125.00. They now have an “overweight” rating on the stock.
• 7/13/2026 – Hinge Health had its price target raised by Morgan Stanley from $72.00 to $108.00. They now have an “overweight” rating on the stock.
• 6/23/2026 – Hinge Health had its price target raised by Wells Fargo & Company from $80.00 to $90.00. They now have an “overweight” rating on the stock.
• 6/17/2026 – Hinge Health had its price target raised by Robert W. Baird from $55.00 to $65.00. They now have a “neutral” rating on the stock.
• 6/15/2026 – Hinge Health had its price target raised by Raymond James Financial, Inc. from $70.00 to $80.00. They now have an “outperform” rating on the stock.
• 6/15/2026 – Hinge Health had its price target raised by Canaccord Genuity Group Inc. from $65.00 to $76.00. They now have a “buy” rating on the stock.
• 6/12/2026 – Hinge Health had its price target raised by KeyCorp from $75.00 to $90.00. They now have an “overweight” rating on the stock.
• 6/11/2026 – Hinge Health had its price target raised by Barclays PLC from $62.00 to $70.00. They now have an “overweight” rating on the stock.
• 6/11/2026 – Hinge Health had its price target raised by Royal Bank Of Canada from $65.00 to $75.00. They now have an “outperform” rating on the stock.
• 6/11/2026 – Hinge Health had its price target raised by Truist Financial Corporation from $79.00 to $85.00. They now have a “buy” rating on the stock.
• 6/11/2026 – Hinge Health had its price target raised by Needham & Company LLC from $63.00 to $76.00. They now have a “buy” rating on the stock.
• 6/10/2026 – Hinge Health had its “overweight” rating reaffirmed by Piper Sandler.
• 6/10/2026 – Hinge Health was given a new $79.00 price target by Stifel Nicolaus.
• 6/6/2026 – Hinge Health was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 6/4/2026 – Hinge Health had its price target raised by Canaccord Genuity Group Inc. from $63.00 to $65.00. They now have a “buy” rating on the stock.
• 5/23/2026 – Hinge Health was upgraded by Wall Street Zen from “buy” to “strong-buy”.

Insider Activity

In related news, major shareholder Insight Holdings Group, Llc sold 1,466,667 shares of Hinge Health stock in a transaction on Monday, June 29th. The shares were sold at an average price of $82.83, for a total value of $121,484,027.61. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Daniel Antonio Perez sold 104,544 shares of the firm’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $55.09, for a total transaction of $5,759,328.96. Following the completion of the sale, the chief executive officer directly owned 35,470 shares of the company’s stock, valued at approximately $1,954,042.30. This represents a 74.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 3,921,100 shares of company stock valued at $299,222,881. Company insiders own 18.92% of the company’s stock.

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.